开云app官网登录入口网页版-官方正版

[GetTopicListResponse(id=2217703, encodeId=9c0e221e7037a, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=929f5936375' target=_blank style='color:#2F92EE;'>#早期复发#</a> <a href='/topic/show?id=e92d9988838' target=_blank style='color:#2F92EE;'>#靶向BCMA#</a>, objectTitle=Blood Cancer J：多发性骨髓瘤患者接受BCMA定向疗法的治疗与应答不良和早期复发相关的临床特征, objectType=article, longId=836806, objectId=0a8683680632, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240731/1722393390330_92910.png, objectUrl=/article/show_article.do?id=0a8683680632, replyNumber=0, likeNumber=60, createdTime=2024-07-31, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0a8683680632, moduleTitle=Blood Cancer J：多发性骨髓瘤患者接受BCMA定向疗法的治疗与应答不良和早期复发相关的临床特征, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0a8683680632)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1819790, encodeId=18691819e90cf, content=<a href='/topic/show?id=e92d9988838' target=_blank style='color:#2F92EE;'>#靶向BCMA#</a>, objectTitle=全球第五款CAR-T疗法获FDA批准上市，靶向BCMA, objectType=article, longId=209485, objectId=5249209485d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5249209485d2, replyNumber=0, likeNumber=85, createdTime=2021-07-30, rootId=0, userName=hxzhang, userId=4f9e287, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5249209485d2, moduleTitle=全球第五款CAR-T疗法获FDA批准上市，靶向BCMA, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5249209485d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1819789, encodeId=ab6c1819e8919, content=<a href='/topic/show?id=e92d9988838' target=_blank style='color:#2F92EE;'>#靶向BCMA#</a>, objectTitle=**靶向BCMA的抗体药物偶联物Blenrep获FDA加速批准：治疗复发或难治性多发性骨髓瘤, objectType=article, longId=198901, objectId=876c19890119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=876c19890119, replyNumber=0, likeNumber=116, createdTime=2021-06-18, rootId=0, userName=hxzhang, userId=4f9e287, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=876c19890119, moduleTitle=**靶向BCMA的抗体药物偶联物Blenrep获FDA加速批准：治疗复发或难治性多发性骨髓瘤, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=876c19890119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1819788, encodeId=02541819e8884, content=<a href='/topic/show?id=e92d9988838' target=_blank style='color:#2F92EE;'>#靶向BCMA#</a>, objectTitle=靶向BCMA的ADC药物belantamab mafodotin，获得FDA咨询小组支持治疗复发或难治的多发性骨髓瘤患者, objectType=article, longId=197577, objectId=fa9619e5777b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa9619e5777b, replyNumber=0, likeNumber=63, createdTime=2021-02-24, rootId=0, userName=hxzhang, userId=4f9e287, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa9619e5777b, moduleTitle=靶向BCMA的ADC药物belantamab mafodotin，获得FDA咨询小组支持治疗复发或难治的多发性骨髓瘤患者, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=fa9619e5777b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1819786, encodeId=5f371819e869b, content=<a href='/topic/show?id=e92d9988838' target=_blank style='color:#2F92EE;'>#靶向BCMA#</a>, objectTitle=葛兰素史克的靶向BCMA抗体偶联药物在多发性骨髓瘤研究中总缓解率达31％, objectType=article, longId=184903, objectId=60b518490392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60b518490392, replyNumber=0, likeNumber=71, createdTime=2020-08-04, rootId=0, userName=hxzhang, userId=4f9e287, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60b518490392, moduleTitle=葛兰素史克的靶向BCMA抗体偶联药物在多发性骨髓瘤研究中总缓解率达31％, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=60b518490392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1819787, encodeId=3cad1819e872c, content=<a href='/topic/show?id=e92d9988838' target=_blank style='color:#2F92EE;'>#靶向BCMA#</a>, objectTitle=欧洲药品管理局接受GSK靶向BCMA的抗体偶联药物belantamab mafodotin的销售授权申请, objectType=article, longId=187393, objectId=e5f218e3936c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5f218e3936c, replyNumber=0, likeNumber=69, createdTime=2020-03-22, rootId=0, userName=hxzhang, userId=4f9e287, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5f218e3936c, moduleTitle=欧洲药品管理局接受GSK靶向BCMA的抗体偶联药物belantamab mafodotin的销售授权申请, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e5f218e3936c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

靶向BCMA

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #早期复发# #靶向BCMA#

Blood Cancer J：多发性骨髓瘤患者接受BCMA定向疗法的治疗与应答不良和早期复发相关的临床特征

2024-07-31发表于上海

hxzhang (审核中...)

前往app查看评论内容

#靶向BCMA#

全球第五款CAR-T疗法获FDA批准上市，靶向BCMA

2021-07-30

hxzhang (审核中...)

前往app查看评论内容

#靶向BCMA#

**靶向BCMA的抗体药物偶联物Blenrep获FDA加速批准：治疗复发或难治性多发性骨髓瘤

2021-06-18

hxzhang (审核中...)

前往app查看评论内容

#靶向BCMA#

靶向BCMA的ADC药物belantamab mafodotin，获得FDA咨询小组支持治疗复发或难治的多发性骨髓瘤患者

2021-02-24

hxzhang (审核中...)

前往app查看评论内容

#靶向BCMA#

葛兰素史克的靶向BCMA抗体偶联药物在多发性骨髓瘤研究中总缓解率达31％

2020-08-04

hxzhang (审核中...)

前往app查看评论内容

#靶向BCMA#

欧洲药品管理局接受GSK靶向BCMA的抗体偶联药物belantamab mafodotin的销售授权申请

2020-03-22

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

#靶向BCMA#

科室

工具

服务